Daniel Barber will succeed Keith Kendall as CEO of Warren-based Aquestive Therapeutics, the company announced Wednesday.
Kendall, the longtime leader of Aquestive, will remain at the company as a consultant through the end of the year.
Aquestive Therapeutics is a pharmaceutical company that aims to advance medicines to solve patients’ problems with current standards of care by providing transformative products to improve their lives.
Kendall joined the company soon after its formation in June 2011 as the chief financial officer, and was promoted to CEO in 2014. He led Aquestive through significant growth under his leadership, including a successful public market debut in 2018, approval of six drug products by the U.S. Food and Drug Administration with more than 10 years of product sales, launch of its first proprietary drug product, Sympazan, in 2018, strengthening the management team, issuance of over 200 patents worldwide and advancement of a late-stage proprietary product pipeline focused on treating diseases of the central nervous system and an earlier stage pipeline for the treatment of severe allergies, including anaphylaxis.
Board Chairman Santo Costa lauded Kendall for his efforts.
“He guided Aquestive through extraordinary growth and built a corporate culture which will serve as a platform for continued future success of the company,” he said. “We are pleased that Mr. Kendall will continue as an adviser to the company and the senior management team through the end of the year. We wish him great success in his future endeavors.”
